APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
86 Views
JCR Pharma (4552 JP): Contract Revenue, Izcargo Comes To Rescue in Q1FY27, FY27 Guidance Reiterated
JCR Pharma revenue rose 13% to ¥9.7B in Q1FY27, driven by Izcargo, contractual payments. FY27 guidance reiterated. Downside potential remains...
98 Views
Primer: Jcr Pharmaceuticals (4552 JP) - Aug 2026
JCR Pharmaceuticals is a specialty biopharmaceutical company focused on rare and genetic diseases, with a key competitive advantage in its...
97 Views
APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm
NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...
92 Views
JCR Pharma (4552 JP): FY26 Seen Off On Contractual Payments, Not Enough Strong Firepower Visible Yet
JCR Pharma revenue up 22% in FY26, driven by Izcargo and contractual payments, price revision impacts Growject. FY27 guidance projects growth....
121 Views